Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00031980
Status:
COMPLETED
Last Update Posted:
2016-07-06
First Post:
2002-03-08
Brief Title:
Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer
Sponsor:
Alliance for Clinical Trials in Oncology
Organization:
Alliance for Clinical Trials in Oncology
Study Overview
Official Title:
Phase II Study of Cyclosporine in T-Cell Large Granular Lymphocytic Leukemia
Status:
COMPLETED
Status Verified Date:
2016-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Cyclosporine may improve low blood counts caused by hematologic cancer
PURPOSE Phase II trial to study the effectiveness of cyclosporine in treating patients who have low blood counts caused by hematologic cancer
PURPOSE Phase II trial to study the effectiveness of cyclosporine in treating patients who have low blood counts caused by hematologic cancer
Detailed Description:
OBJECTIVES
Determine the frequency of cytopenic response in patients with T-cell large granular lymphocytic leukemia treated with cyclosporine
OUTLINE This is a multicenter study
Patients receive oral cyclosporine every 12 hours Treatment continues in the absence of disease progression or unacceptable toxicity
Patients are followed every 4 months for 1 year and then every 6 months for 9 years
PROJECTED ACCRUAL A total of 9-30 patients will be accrued for this study within 3 years
Determine the frequency of cytopenic response in patients with T-cell large granular lymphocytic leukemia treated with cyclosporine
OUTLINE This is a multicenter study
Patients receive oral cyclosporine every 12 hours Treatment continues in the absence of disease progression or unacceptable toxicity
Patients are followed every 4 months for 1 year and then every 6 months for 9 years
PROJECTED ACCRUAL A total of 9-30 patients will be accrued for this study within 3 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CALGB-10003 | None | None | None |
| CDR0000069246 | REGISTRY | NCI Physician Data Query | None |